ADX-248, which replaces ADX-743, is being developed for the treatment of metabolic inflammation, including obesity and hypertriglyceridemia
Vitiligo, affecting over 90 per cent of patients in its non-segmental form, is characterized by symmetrical white patches on both sides of the body
Approval based on pivotal KOMET Phase III trial demonstrating significant tumour reduction in adults with NF1
Test delivers results in just 18 minutes, enabling faster laboratory workflows and patient management during outbreaks
Tourmaline is now an indirect wholly owned subsidiary of Novartis
Partnership combines MilliporeSigma’s chemistry and organoid expertise with Promega’s assay technologies
The acquisition will follow the planned separation of Avidity’s early-stage precision cardiology programs into a new, independent company
Adverum's lead program, Ixo-vec, is a Phase 3 gene therapy designed to treat vision loss associated with wet age-related macular degeneration with a single intravitreal dose
Efdoralprin Alfa was well tolerated, with a safety profile comparable to plasma-derived therapy
Yesintek and Yesintek I.V. are approved for the treatment of moderate to severe plaque psoriasis in adults and pediatric patients
Subscribe To Our Newsletter & Stay Updated
